The Impact of the Rs1044457 Polymorphism in the CMPK1 Gene on the Response Rate to Gemcitabine-Based Chemotherapy in Metastatic NSCLC Patients.

Adv Genet (Hoboken) · 2025 · PMC12245479 · PMID 40657553

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Following 4–6 cycles of treatment, the mean final tumour size in responsive patients reduced to (34.6 ± 30.94 cm), significantly lower than that of non‐responsive patients (57.86 ± 43.8 cm) with a highly significant difference.

also in 132,142 other papers

did not reach statistical significanceno p-value reported

Therapeutic and Clinical Characteristics of the Patients The prevalence of hypertension and ischemic heart diseases (IHD) exhibited a slightly higher incidence among non‐responsive patients (37.5% and 14.58%, respectively) compared to responsive patients (24% and 10%, respectively); however, these disparities did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.